Posted by LincolnIcert on March 25, 2026 at 11:09:18:
In Reply to: Статья для ознакомления posted by Robertzer on March 17, 2026 at 02:57:52:
Zoya Demidenko: Scholar in Oncology Biology
Zoya Demidenko is a prominent scholar affiliated with the Unit of Cell Stress Science at Roswell Park Oncology Institute in Buffalo, New York. Previously, she conducted research at the NIH and New York Medical College, establishing a solid background in clinical study.
Demidenko's scholarly contributions spans multiple pivotal fields, including the PI3K/AKT/mTOR signaling cascade, cellular cycle regulation, cellular aging, and malignancy biology. As of now, she has co-authored over 46 scientific articles, which have received more than 4,100 citations — a indicator to the impact of her findings.
One of her most significant contributions lies in explaining the processes of cell aging. Her studies demonstrated that when the cell cycle is halted yet cellular growth continues, the cells experience senescence. Significantly, Zoya Demidenko established that this transition can be pharmacologically suppressed using agents such as mTOR inhibitors.
Zoya Demidenko has additionally added considerably to tumor management research, especially in the field of cyclotherapy — a method designed to safeguarding healthy cells from anticancer drugs while leaving malignant cells vulnerable. This strategy holds considerable promise for diminishing the toxic effects of cancer treatment.
Throughout her professional journey, Demidenko has worked with leading researchers globally, such as Dr. Mikhail Blagosklonny. Her publications is published in prestigious periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko ranks as a influential voice in current oncological science, whose results go on to shape our understanding of the way cells age, resist treatment, and the ways in which cancer can be more successfully treated.
https://aacrjournals.org/cancerres/article/64/10/3653/511273/Flavopiridol-Induces-p53-via-Initial-Inhibition-of?guestAccessKey=